. 2018 Oct 1;53(6):2433–2444. doi: 10.3892/ijo.2018.4580

Table I.

Association between miR-103 and LATS2 expression levels with the clinicopathological characteristic of patients with hepatocellular carcinoma.

Variable	Total no. of patients, n=120 (%)	miR-103		P-value	LATS2		P-value
Variable	Total no. of patients, n=120 (%)	Low expression	High expression	P-value	Low expression	High expression	P-value
Age (years)				0.057			0.120
<50	49 (40.8)	10	39		37	12
≥50	71 (59.2)	26	45		44	27
Sex				0.496			0.349
Female	21 (17.5)	5	16		16	5
Male	99 (82.5)	31	68		65	34
HBsAg				0.955			0.903
Positive	76 (63.3)	15	61		51	25
Negative	44 (36.7)	21	23		30	14
AFP (ng/ml)				0.01^a			0.422
<400	97 (80.8)	24	73		50	27
≥400	23 (19.2)	12	11		31	12
Cirrhosis				0.741			0. 903
Yes	76 (63.3)	22	54		51	25
No	44 (36.7)	14	30		30	14
Tumor size (cm)				0.007^a			0.032^a
<5	48 (40)	21	27		27	21
≥5	72 (60)	15	57		54	18
Tumor multiplicity				0.228			0.992
Single	77 (64.2)	26	51		52	25
Multiple	43 (35.8)	10	33		29	14
Differentiation				0.318			0.383
Well-moderate	53 (44.2)	17	36		38	15
Poor-undifferentiated	67 (55.8)	19	48		43	24
Microscopic vascular invasion				<0.001^b			0.001^a
Yes	39 (32.5)	28	11		18	21
No	81 (67.5)	8	73		63	18
Stage				<0.001^b			0.021^a
I–II	78 (65)	32	46		47	31
III–IV (with metastasis)	42 (35)	4	38		34	8

Values in bold indicate statistical significance (^aP<0.05 and ^bP<0.01).